Baker Bros. Advisors’s Biogen BIIB Stock Holding History

Baker Bros. Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16,500	Closed	-$4.51M	–	121
2017 Q1	$4.51M	Hold	16,500	–	–	0.04%	67
2016 Q4	$4.68M	Buy	+16,500	New	+$4.89M	0.05%	66

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baker Bros. Advisors's BIIB Position: Q2 2017 in Review

Baker Bros. Advisors sold out of Biogen (BIIB) in Q2 2017, closing a stake of 16,500 shares — an estimated $4.51M sold.

Baker Bros. Advisors first reported a position in BIIB in Q4 2016 and held it in 2 quarters. The position peaked at $4.68M in Q4 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

Baker Bros. Advisors reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
Baker Bros. Advisors sold 16,500 Biogen shares in Q2 2017, an estimated $4.51M.
Baker Bros. Advisors first reported a position in Biogen in Q4 2016 and held it in 2 quarters.
Baker Bros. Advisors's Biogen position peaked at $4.68M in Q4 2016.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.